- Home
- SNTI vs IPSC Comparison
SNTI vs IPSC Comparison
Compare SNTI & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- IPSC
- Stock Information
- Founded
- SNTI 2016
- IPSC 2019
- Country
- SNTI United States
- IPSC United States
- Employees
- SNTI N/A
- IPSC N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- SNTI Health Care
- IPSC Health Care
- Exchange
- SNTI Nasdaq
- IPSC Nasdaq
- Market Cap
- SNTI 39.6M
- IPSC 43.6M
- IPO Year
- SNTI N/A
- IPSC 2021
- Fundamental
- Price
- SNTI $1.39
- IPSC $0.51
- Analyst Decision
- SNTI Strong Buy
- IPSC Strong Buy
- Analyst Count
- SNTI 2
- IPSC 5
- Target Price
- SNTI $8.50
- IPSC $3.33
- AVG Volume (30 Days)
- SNTI 121.1K
- IPSC 526.9K
- Earning Date
- SNTI 11-13-2025
- IPSC 11-04-2025
- Dividend Yield
- SNTI N/A
- IPSC N/A
- EPS Growth
- SNTI N/A
- IPSC N/A
- EPS
- SNTI N/A
- IPSC N/A
- Revenue
- SNTI N/A
- IPSC $114,128,000.00
- Revenue This Year
- SNTI N/A
- IPSC $1,589.94
- Revenue Next Year
- SNTI $150.00
- IPSC N/A
- P/E Ratio
- SNTI N/A
- IPSC N/A
- Revenue Growth
- SNTI N/A
- IPSC 5491.77
- 52 Week Low
- SNTI $1.26
- IPSC $0.34
- 52 Week High
- SNTI $16.94
- IPSC $1.86
- Technical
- Relative Strength Index (RSI)
- SNTI 39.50
- IPSC 47.68
- Support Level
- SNTI $1.33
- IPSC $0.48
- Resistance Level
- SNTI $1.42
- IPSC $0.52
- Average True Range (ATR)
- SNTI 0.07
- IPSC 0.02
- MACD
- SNTI 0.02
- IPSC 0.00
- Stochastic Oscillator
- SNTI 44.83
- IPSC 79.31
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.